Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Control of Myopia Using Novel Spectacle Lens Designs
NCT03623074 · View on ClinicalTrials.gov ↗
Study Summary
Randomized, controlled, multisite, subject-and observer-masked, 3-arm parallel group clinical trial of 36-month duration to evaluate the safety and efficacy of a novel spectacle lens design in reducing the progression of juvenile myopia.
Conditions Studied
Interventions
- DEVICE Novel spectacle lens design
- DEVICE Spectacle lenses
Study Locations (14)
New York
- SUNY School of Optometry — New York
- Sacco Eye Group — Vestal
- Dept of Clinical Research, South Shore Eye Care, LLP — Wantagh
Florida
- Sabal Eye Care — Longwood
- Visual Performance Center — Pensacola
California
- Golden Optometric Group — Whittier
Kansas
- Kannarr Eye Care — Pittsburg
Louisiana
- Eye Associates of Northeast Louisiana (DBA Haik Humble Eye Center) Research Dept — West Monroe
Missouri
- Advanced Eyecare, PC — Raytown
South Dakota
- Dunes Eye Consultants — Dakota Dunes
Tennessee
- Total Eye Care — Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2018-07-16 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03623074
The ClinicalTrials.gov registry entry for NCT03623074 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 266 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SightGlass Vision, which has 7 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Juvenile Myopia appearing as the primary indexed condition, and to 2 interventions — of which Novel spectacle lens design is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03623074 reports 14 study locations spanning 11 distinct geographic areas — top geographies include New York, Florida, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03623074 about?
NCT03623074 is a clinical study titled "Control of Myopia Using Novel Spectacle Lens Designs". Randomized, controlled, multisite, subject-and observer-masked, 3-arm parallel group clinical trial of 36-month duration to evaluate the safety and efficacy of a novel spectacle lens design in reducing the progression of juvenile myopia.
What is the current status of trial NCT03623074?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 266 participants. The study started on 2018-07-16. Estimated completion is 2026-03-31.
What conditions does trial NCT03623074 study?
This clinical trial studies the following conditions: Juvenile Myopia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03623074?
The interventions under investigation include: Novel spectacle lens design (DEVICE), Spectacle lenses (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03623074?
This trial is sponsored by SightGlass Vision, which has 7 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03623074 being conducted?
This trial has 14 study locations across California, Florida, Kansas, Louisiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.